ARCT - Arcturus Therapeutics Holdings Inc

Arcturus Therapeutics Holdings Inc., an RNA drug company, focuses on the treatment of liver and respiratory diseases. The company is headquartered in San Diego, California.

52W High

$25.88

52W Low

$8.04

MA Status:

50D: Above 200D: Above

Beta (~1 neutral, <0.9 lower risk)

2.39

Valuation

Attractive

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

2.48

EV/EBITDA (<8 favorable)

-25.67

EV/Revenue (<3 favorable)

2.87

P/S (TTM) (<3 favorable)

3.97

P/B (<3 favorable)

2.10

Ownership

Institution‑heavy

Source: Overview

Insiders (1–5% typical)

7.88%

Institutions (25–75% balanced)

89.26%

Shares Outstanding

27,154,500

Float

25,017,500

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

122,122,000

Gross Profit (TTM)

-70,926,000

EPS (TTM)

-2.22

Profit Margin (>10% good)

-0.49%

Operating Margin (TTM) (higher better)

-0.41%

ROE (TTM) (>15% strong)

-0.25%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

-0.43

Momentum

Bearish momentum

Value

0.7716

0.8687

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025